
  
    
      
        Background_NNP
        Chronically_NNP elevated_VBD cortisol_NN levels_NNS caused_VBN by_IN Cushing_NNP 's_POS
        syndrome_NN leads_VBZ to_TO central_JJ obesity_NN [_NN 1_CD ]_NN while_IN the_DT reduction_NN
        of_IN cortisol_NN caused_VBN by_IN Addison_NNP 's_POS disease_NN leads_VBZ to_TO decreased_VBN
        body_NN weight_NN [_NN 2_CD ]_NN ._. Obesity_NNP in_IN several_JJ rodent_NN models_NNS is_VBZ
        also_RB associated_VBN with_IN elevated_JJ corticosterone_NN levels_NNS ,_, and_CC
        adrenalectomy_NN reverses_VBZ some_DT of_IN the_DT phenotypes_NNS associated_VBN
        with_IN these_DT forms_NNS of_IN obesity_NN [_NN 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ._. Furthermore_RB ,_,
        elevated_VBD corticosterone_NN production_NN can_MD cause_VB a_DT metabolic_JJ
        syndrome_NN [_NN 8_CD ]_NN ._. These_DT data_NNS suggest_VBP that_DT reduction_NN of_IN
        glucocorticoid_NN production_NN might_MD therefore_RB constitute_VB a_DT
        plausible_JJ clinical_JJ strategy_NN to_TO treat_VB obesity_NN ._. On_IN the_DT other_JJ
        hand_NN ,_, obesity_NN in_IN humans_NNS does_VBZ not_RB generally_RB entail_VB elevated_VBD
        plasma_NN cortisol_NN [_NN 9_CD 10_CD 11_CD 12_CD 13_CD ]_NN and_CC it_PRP is_VBZ not_RB clear_JJ how_WRB
        effective_JJ reduction_NN of_IN glucocorticoid_NN production_NN would_MD be_VB
        to_TO reverse_VB obesity_NN if_IN glucocorticoid_NN production_NN were_VBD
        otherwise_RB normal_JJ ._. Nevertheless_RB ,_, pharmacological_JJ antagonism_NN
        of_IN glucocorticoid_NN (_( type_NN II_NNP )_) receptor_NN by_IN mifepristone_NN
        (_( RU_NNP 486_CD )_) was_VBD reported_VBN to_TO reverse_VB high_JJ fat_JJ diet-induced_JJ
        obesity_NN [_NN 14_CD ]_NN ._. Since_IN diet-induced_JJ obesity_NN does_VBZ not_RB entail_VB
        elevated_VBD glucocorticoid_NN levels_NNS [_NN 15_CD 16_CD 17_CD ]_NN ,_, this_DT result_NN
        suggests_VBZ that_DT reduction_NN of_IN glucocorticoid_NN levels_NNS would_MD
        reverse_VB obesity_NN even_RB when_WRB glucocorticoid_NN levels_NNS are_VBP not_RB
        elevated_VBD ._.
        Although_IN the_DT mechanisms_NNS through_IN which_WDT adrenalectomy_NN acts_NNS
        to_TO reverse_VB obesity_NN is_VBZ not_RB entirely_RB clear_JJ ,_, it_PRP is_VBZ plausible_JJ
        that_IN the_DT mechanisms_NNS entail_VB enhanced_VBN hypothalamic_JJ POMC_NNP
        production_NN [_NN 6_CD ]_NN ._. Hypothalamic_NNP POMC_NNP mRNA_NN is_VBZ reduced_VBN in_IN
        several_JJ forms_NNS of_IN obesity_NN [_NN 18_CD 19_CD 20_CD ]_NN ._. Conversely_RB ,_,
        reversal_NN of_IN obese_NN phenotypes_NNS by_IN adrenalectomy_NN is_VBZ associated_VBN
        with_IN a_DT restoration_NN of_IN hypothalamic_JJ POMC_NNP mRNA_NN tone_NN in_IN
        leptin-deficient_JJ 
        ob_NN /_NN ob_NN mice_NNS [_NN 6_CD ]_NN ._. Furthermore_RB ,_, the_DT
        melanocortin_NN agonist_NN MTII_NNP (_( which_WDT mimics_VBZ the_DT key_JJ
        anti-obesity_JJ product_NN of_IN POMC_NNP ,_, alpha-_NN MSH_NNP )_) reduces_VBZ body_NN
        weight_NN in_IN diet-induced_JJ obesity_NN [_NN 21_CD ]_NN ._. On_IN the_DT other_JJ hand_NN ,_,
        the_DT effect_NN of_IN diet-induced_JJ obesity_NN on_IN hypothalamic_JJ POMC_NNP
        mRNA_NN is_VBZ somewhat_RB complex_JJ and_CC may_MD depend_VB on_IN the_DT genetic_JJ
        background_NN [_NN 22_CD 23_CD ]_NN ,_, and_CC duration_NN of_IN the_DT diet_NN [_NN 24_CD 25_CD ]_NN
        or_CC composition_NN [_NN 23_CD ]_NN of_IN the_DT diet_NN ._. Furthermore_RB ,_, the_DT effect_NN
        of_IN adrenalectomy_NN on_IN hypothalamic_JJ POMC_NNP mRNA_NN may_MD also_RB depend_VB
        genetic_JJ background_NN [_NN 6_CD 26_CD 27_CD ]_NN ._. Nevertheless_RB ,_, we_PRP
        hypothesized_VBN that_IN if_IN adrenalectomy_NN enhanced_VBD hypothalamic_JJ
        POMC_NNP mRNA_NN in_IN diet-induced_JJ obesity_NN in_IN mice_NNS ,_, as_IN in_IN
        leptin-deficient_JJ mice_NNS ,_, adrenalectomy_NN would_MD also_RB reverse_VB
        obese_NN phenotypes_NNS in_IN mice_NNS that_WDT became_VBD obese_NN due_JJ to_TO a_DT
        high-fat_JJ diet_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP observed_VBD that_DT
        adrenalectomy_NN did_VBD indeed_RB lead_VB to_TO a_DT remarkable_JJ enhancement_NN
        of_IN hypothalamic_JJ POMC_NNP mRNA_NN tone_NN in_IN mice_NNS made_VBD obese_NN on_IN a_DT
        high-fat_JJ diet_NN ;_: surprisingly_RB ,_, however_RB ,_, adrenalectomy_NN did_VBD not_RB
        reverse_VB diet-induced_JJ obesity_NN ._.
      
      
        Results_NNS
        
          Effects_NNPS diet_NN and_CC adrenalectomy_NN on_IN body_NN weight_NN ,_,
          adipose_NN weight_NN and_CC caloric_JJ intake_NN
          Prior_RB to_TO adrenalectomy_NN ,_, mice_NNS on_IN the_DT high-fat_JJ diet_NN
          gained_VBD body_NN weight_NN about_IN five-fold_JJ more_RBR rapidly_RB than_IN
          chow-fed_JJ mice_NNS in_IN the_DT first_JJ seven_CD days_NNS on_IN the_DT high-fat_JJ
          diet_NN (_( chow_NN fed_VBD mice_NNS gained_VBD 0_CD ._. 68_CD ±_NN 0_CD ._. 13_CD g_SYM compared_VBN to_TO
          high-fat_JJ diet_NN mice_NNS which_WDT gained_VBD 5_CD ._. 1_CD ±_NN 0_CD ._. 2_CD g_SYM over_IN the_DT
          first_JJ seven_CD days_NNS on_IN the_DT diet_NN ;_: p_NN <_NN 0_CD ._. 05_CD )_) ._. At_IN the_DT end_NN of_IN
          the_DT five_CD week_NN period_NN ,_, mice_NNS on_IN the_DT high-fat_JJ diet_NN ,_, both_DT
          sham-operated_JJ and_CC adrenalectomized_JJ ,_, exhibited_VBN a_DT
          significant_JJ elevation_NN of_IN both_DT body_NN weight_NN (_( Fig_NNP ._. 1_LS A_DT )_) and_CC
          adipose_NN weight_NN (_( Fig_NNP ._. 1_LS B_NNP )_) compared_VBN to_TO the_DT chow_NN fed_VBD mice_NNS ,_,
          both_DT sham-operated_JJ and_CC adrenalectomized_JJ ._. Although_IN
          adrenalectomy_NN initially_RB caused_VBD a_DT greater_JJR loss_NN of_IN body_NN
          weight_NN in_IN the_DT diet-induced_JJ obese_NN mice_NNS (_( high_JJ fat-diet_JJ
          sham-operated_JJ mice_NNS lost_VBD 1_CD ._. 2_CD ±_NN 0_CD ._. 5_CD g_SYM seven_CD days_NNS after_IN
          surgery_NN compared_VBN to_TO diet_NN adrenalectomized_JJ mice_NNS who_WP lost_VBD
          2_CD ._. 9_CD ±_NN 0_CD ._. 3_CD g_SYM ;_: p_NN <_NN 0_CD ._. 05_CD )_) ,_, by_IN two_CD weeks_NNS after_IN the_DT surgery_NN
          body_NN weight_NN in_IN both_DT groups_NNS had_VBD fully_RB recovered_VBN body_NN
          weight_NN to_TO pre-surgery_JJ levels_NNS ._. In_IN the_DT sham-operated_JJ mice_NNS ,_,
          mass_NN of_IN food_NN intake_NN was_VBD significantly_RB decreased_VBN in_IN mice_NNS
          on_IN the_DT high_JJ fat_JJ diet_NN compared_VBN to_TO the_DT chow-fed_JJ mice_NNS (_( Fig_NNP ._.
          1_LS C_NNP )_) ._. Although_IN the_DT diet-induced_JJ obese_NN mice_NNS consumed_VBD more_JJR
          (_( calculated_VBN )_) calories_NNS than_IN chow-fed_JJ mice_NNS during_IN the_DT first_JJ
          week_NN on_IN the_DT diet_NN (_( during_IN which_WDT the_DT most_RBS rapid_JJ weight_NN gain_NN
          was_VBD observed_VBN )_) ,_, by_IN the_DT fifth_JJ week_NN they_PRP were_VBD hypophagic_JJ
          both_DT in_IN terms_NNS of_IN mass_NN of_IN food_NN consumed_VBN (_( g_SYM /_NN day_NN )_) and_CC in_IN
          calculated_VBN calories_NNS consumed_VBN (_( calories_NNS /_NN day_NN )_) (_( the_DT chow_NN
          sham-operated_JJ mice_NNS consumed_VBD 16_CD ._. 1_LS ±_NN 0_CD ._. 8_CD [_NN calculated_VBD ]_NN
          cal_NN /_NN day_NN compared_VBN to_TO 12_CD ._. 9_CD ±_NN 1_CD ._. 2_CD cal_NN /_NN day_NN for_IN the_DT diet_NN
          sham-operated_JJ mice_NNS ;_: p_NN <_NN 0_CD ._. 05_CD )_) ._.
          Surprisingly_RB ,_, adrenalectomy_NN had_VBD no_DT effect_NN on_IN body_NN
          weight_NN (_( Fig_NNP ._. 1_LS A_DT )_) ,_, adipose_NN weight_NN (_( Fig_NNP ._. 1_LS B_NNP )_) or_CC food_NN intake_NN
          (_( Fig_NNP ._. 1_LS C_NNP )_) for_IN mice_NNS on_IN either_DT the_DT chow_NN diet_NN or_CC the_DT high_JJ
          fat_JJ diet_NN ,_, five_CD weeks_NNS after_IN initiation_NN of_IN the_DT diet_NN and_CC
          three_CD weeks_NNS after_IN adrenalectomy_NN ._.
        
        
          Effects_NNPS of_IN diet_NN and_CC adrenalectomy_NN on_IN serum_NN
          hormones_NNS ,_, glucose_NN tolerance_NN and_CC metabolic_JJ rate_NN
          Serum_NNP leptin_NN was_VBD elevated_VBD in_IN mice_NNS on_IN the_DT high-fat_JJ
          diet_NN ,_, concordant_NN with_IN the_DT development_NN of_IN obesity_NN ,_, but_CC
          adrenalectomy_NN had_VBD no_DT effect_NN on_IN leptin_NN levels_NNS (_( Table_NNP I_PRP )_) ._.
          Neither_DT insulin_NN nor_CC glucose_NN was_VBD significantly_RB influenced_VBN
          by_IN either_DT diet_NN or_CC adrenalectomy_NN (_( Table_NNP I_PRP )_) ._. The_DT high_JJ fat_JJ
          diet_NN had_VBD no_DT effect_NN on_IN serum_NN corticosterone_NN ,_, but_CC as_IN
          expected_VBN adrenalectomy_NN reduced_VBD serum_NN corticosterone_NN by_IN
          over_IN 70_CD %_NN in_IN mice_NNS on_IN both_DT diets_NNS (_( Table_NNP I_PRP )_) ._. While_IN this_DT
          effect_NN was_VBD significant_JJ ,_, consistent_JJ with_IN previous_JJ studies_NNS
          [_NN 6_CD ]_NN ,_, adrenalectomy_NN did_VBD not_RB eliminate_VB detectable_JJ
          corticosterone_NN completely_RB ._.
          Glucose_NNP tolerance_NN was_VBD strikingly_RB impaired_VBN after_IN only_RB
          one_CD week_NN on_IN the_DT high_JJ fat_JJ diet_NN (_( Fig_NNP ._. 2_LS ;_: p_NN <_NN 0_CD ._. 0001_CD )_) ._.
          Adrenalectomy_NNP slightly_RB but_CC significantly_RB improved_VBN glucose_NN
          tolerance_NN on_IN the_DT high_JJ fat_JJ diet_NN (_( Fig_NNP ._. 2_LS ;_: p_NN <_NN 0_CD ._. 05_CD )_) ._.
          Total_JJ heat_NN production_NN (_( not_RB normalized_JJ to_TO body_NN weight_NN )_) was_VBD
          significantly_RB elevated_VBD by_IN the_DT high_JJ fat_JJ diet_NN (_( Fig_NNP ._. 3_LS A_DT ;_: p_NN
          <_NN 0_CD ._. 0001_CD )_) and_CC adrenalectomy_NN led_VBN to_TO a_DT slight_JJ but_CC
          statistical_JJ further_JJ increase_NN in_IN heat_NN production_NN in_IN the_DT
          diet-induced_JJ obese_NN mice_NNS (_( Fib_NNP ._. 3_LS B_NNP ;_: p_NN <_NN 0_CD ._. 002_CD )_) ._. VO_NNP 
          2_CD (_( oxygen_NN consumption_NN normalized_JJ to_TO
          body_NN weight_NN )_) was_VBD reduced_VBN in_IN mice_NNS on_IN the_DT high_JJ fat_JJ diet_NN
          (_( Fig_NNP ._. 4_LS A_DT ;_: p_NN <_NN 0_CD ._. 0001_CD )_) and_CC as_IN with_IN total_JJ heat_NN
          production_NN adrenalectomy_NN slightly_RB but_CC statistically_RB
          increased_VBN VO_NNP 
          2_CD in_IN the_DT diet-induced_JJ obese_NN mice_NNS group_NN
          (_( Fig_NNP ._. 4_LS B_NNP ;_: p_NN <_NN 0_CD ._. 05_CD )_) ._. Therefore_RB adrenalectomy_NN led_VBN to_TO a_DT
          slight_JJ but_CC statistical_JJ increase_NN in_IN metabolic_JJ rate_NN as_RB well_RB
          as_IN glucose_NN tolerance_NN in_IN the_DT diet-induced_JJ mice_NNS ._.
        
        
          Effects_NNPS of_IN diet_NN and_CC adrenalectomy_NN on_IN pituitary_JJ POMC_NNP
          mRNA_NN
          Although_IN diet_NN did_VBD not_RB influence_VB pituitary_JJ POMC_NNP mRNA_NN ,_,
          adrenalectomy_NN increased_VBD pituitary_JJ POMC_NNP expression_NN in_IN mice_NNS
          on_IN both_DT diets_NNS (_( Table_NNP I_PRP )_) ._. Together_RB with_IN the_DT reduction_NN in_IN
          serum_NN corticosterone_NN ,_, this_DT induction_NN of_IN pituitary_JJ POMC_NNP
          indicates_VBZ that_IN the_DT adrenalectomy_NN produced_VBD a_DT
          physiologically_RB significant_JJ reduction_NN in_IN corticosterone_NN
          tone_NN ._.
        
        
          Effects_NNPS of_IN diet_NN and_CC adrenalectomy_NN on_IN hypothalamic_JJ
          POMC_NNP mRNA_NN
          The_DT high-fat_JJ diet_NN led_VBN to_TO a_DT slight_JJ but_CC significant_JJ
          increase_NN in_IN hypothalamic_JJ POMC_NNP mRNA_NN in_IN sham-operated_JJ mice_NNS
          (_( Figure_NN 5_CD A_DT )_) ._. Adrenalectomy_NNP produced_VBD a_DT non-significant_JJ
          trend_NN toward_IN an_DT increase_NN in_IN hypothalamic_JJ POMC_NNP mRNA_NN in_IN
          sham-operated_JJ mice_NNS ,_, but_CC a_DT 5_CD -_: fold_VB induction_NN of_IN POMC_NNP mRNA_NN
          in_IN mice_NNS on_IN the_DT high-fat_JJ diet_NN (_( Fig_NNP ._. 5_LS A_DT )_) ._. The_DT high-fat_JJ diet_NN
          did_VBD not_RB significantly_RB influence_VB hypothalamic_JJ AGRP_NNP in_IN this_DT
          study_NN ,_, but_CC surprisingly_RB adrenalectomy_NN slightly_RB stimulated_VBN
          hypothalamic_JJ AGPR_NNP mRNA_NN levels_NNS (_( Fig_NNP ._. 5_LS B_NNP )_) ._.
        
      
      
        Discussion_NNP
        The_DT high_JJ fat_JJ diet_NN used_VBN in_IN this_DT study_NN led_VBN to_TO the_DT
        development_NN of_IN obesity_NN over_IN the_DT course_NN of_IN five_CD weeks_NNS as_IN
        expected_VBN (_( Fig_NNP ._. 1_LS A_DT )_) ._. As_IN observed_VBD in_IN leptin-deficient_JJ 
        ob_NN /_NN ob_NN mice_NNS ,_, adrenalectomy_NN in_IN
        diet-induced_JJ obese_NN mice_NNS led_VBN to_TO a_DT striking_JJ increase_NN in_IN
        hypothalamic_JJ POMC_NNP mRNA_NN (_( Fig_NNP ._. 5_LS A_DT )_) ._. This_DT elevation_NN in_IN
        hypothalamic_JJ POMC_NNP with_IN only_RB a_DT very_RB modest_JJ increase_NN in_IN the_DT
        antagonist_NN AGRP_NNP mRNA_NN (_( Fig_NNP ._. 5_LS B_NNP )_) would_MD be_VB expected_VBN to_TO lead_VB to_TO
        significant_JJ amelioration_NN of_IN obese_NN phenotypes_NNS ,_, consistent_JJ
        with_IN effects_NNS of_IN adrenalectomy_NN on_IN other_JJ forms_NNS of_IN obesity_NN [_NN 3_CD
        4_CD 5_CD 6_CD 7_CD ]_NN ._. Indeed_RB adrenalectomy_NN initially_RB led_VBD to_TO a_DT greater_JJR
        loss_NN of_IN body_NN weight_NN after_IN surgery_NN in_IN the_DT diet-induced_JJ obese_NN
        mice_NNS (_( results_NNS in_IN text_NN above_IN )_) ._. Surprisingly_RB ,_, however_RB ,_,
        adrenalectomized_JJ mice_NNS regained_VBD all_PDT the_DT weight_NN lost_VBD after_IN
        surgery_NN (_( Fig_NNP ._. 1_LS A_DT )_) ,_, and_CC adrenalectomy_NN also_RB failed_VBD to_TO reduce_VB
        food_NN intake_NN ,_, adipose_NN weight_NN ,_, or_CC plasma_NN leptin_NN in_IN the_DT obese_NN
        mice_NNS ._.
        As_IN has_VBZ been_VBN observed_VBN in_IN other_JJ models_NNS of_IN obesity_NN due_JJ to_TO a_DT
        high-fat_JJ diet_NN ,_, the_DT diet-induced_JJ obese_NN mice_NNS also_RB became_VBD
        hypophagic_JJ compared_VBN to_TO the_DT chow_NN fed_VBD mice_NNS and_CC compared_VBN to_TO
        the_DT hyperphagia_NN exhibited_VBN by_IN mice_NNS in_IN the_DT first_JJ two_CD weeks_NNS on_IN
        a_DT high_JJ fat_JJ diet_NN [_NN 28_CD ]_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. The_DT hypophagia_NN of_IN
        diet-induced_JJ obesity_NN may_MD be_VB related_VBN to_TO the_DT modestly_RB
        elevated_VBD hypothalamic_JJ POMC_NNP ,_, whose_WP$ product_NN alpha-_NN MSH_NNP is_VBZ a_DT
        known_VBN anorexic_JJ agent_NN [_NN 20_CD 29_CD ]_NN ._. In_IN turn_NN ,_, the_DT induction_NN of_IN
        hypothalamic_JJ POMC_NNP by_IN the_DT high-fat_JJ diet_NN might_MD have_VB been_VBN due_JJ
        in_IN part_NN to_TO the_DT elevation_NN of_IN leptin_NN in_IN diet-induced_JJ obese_NN
        mice_NNS (_( Table_NNP I_PRP )_) ._. The_DT further_JJ elevation_NN in_IN POMC_NNP expression_NN
        observed_VBD after_IN adrenalectomy_NN of_IN the_DT obese_NN mice_NNS could_MD
        plausibly_RB be_VB due_JJ to_TO elevated_VBD leptin_NN combined_VBN with_IN decreased_VBD
        glucocorticoids_NNS ,_, since_IN glucocorticoids_NNS may_MD antagonize_VB the_DT
        effects_NNS leptin_NN [_NN 30_CD ]_NN ._.
        Tolerance_NNP to_TO a_DT glucose_NN load_NN was_VBD also_RB impaired_VBN in_IN mice_NNS
        after_IN one_CD week_NN on_IN the_DT high-fat_JJ diet_NN ,_, suggesting_VBG the_DT
        development_NN of_IN insulin_NN resistance_NN (_( Fig_NNP ._. 2_LS )_) ._. However_RB ,_,
        neither_DT basal_NN blood_NN glucose_NN nor_CC serum_NN insulin_NN levels_NNS were_VBD
        elevated_VBD by_IN the_DT high_JJ fat_JJ diet_NN at_IN this_DT time_NN point_NN (_( Table_NNP I_PRP )_) ._.
        We_PRP have_VBP observed_VBN in_IN other_JJ studies_NNS that_WDT basal_NN
        hyperinsulinemia_NN is_VBZ not_RB detected_VBN until_IN mice_NNS have_VBP been_VBN on_IN
        the_DT high-fat_JJ diet_NN for_IN at_IN least_JJS two_CD months_NNS (_( unpublished_JJ
        observations_NNS )_) ._. Adrenalectomy_NNP led_VBD to_TO only_RB minor_JJ improvement_NN
        in_IN impaired_VBN glucose_NN tolerance_NN (_( Fig_NNP ._. 2_LS )_) and_CC it_PRP did_VBD not_RB
        affect_VB blood_NN glucose_NN or_CC serum_NN insulin_NN levels_NNS (_( Table_NNP I_PRP )_) ._.
        The_DT key_JJ observation_NN concerning_VBG food_NN intake_NN was_VBD that_DT
        adrenalectomy_NN did_VBD not_RB significantly_RB influence_VB food_NN intake_NN
        on_IN either_DT diet_NN ._. Mice_NNS on_IN the_DT high-fat_JJ diet_NN ate_VBD less_JJR than_IN the_DT
        mice_NNS on_IN the_DT chow_NN diet_NN ,_, both_DT in_IN terms_NNS of_IN mass_NN consumed_VBN and_CC ,_,
        surprisingly_RB ,_, in_IN terms_NNS of_IN total_JJ calculated_VBN caloric_JJ intake_NN
        (_( Fig_NNP ._. 1_LS C_NNP )_) ._. Since_IN caloric_JJ intake_NN was_VBD calculated_VBN without_IN
        normalization_NN to_TO body_NN weight_NN ,_, for_IN purposes_NNS of_IN analyzing_VBG
        metabolic_JJ economy_NN the_DT most_RBS valid_JJ comparison_NN of_IN total_JJ
        caloric_JJ intake_NN is_VBZ to_TO total_VB caloric_JJ expenditure_NN (_( total_JJ heat_NN
        production_NN )_) without_IN normalization_NN to_TO body_NN weight_NN ,_, as_IN shown_VBN
        in_IN Figure_NN 3_CD ._. Although_IN the_DT effect_NN was_VBD small_JJ ,_, the_DT increase_NN on_IN
        the_DT high-fat_JJ diet_NN in_IN total_JJ heat_NN production_NN without_IN
        normalization_NN to_TO body_NN weight_NN was_VBD significant_JJ (_( statistical_JJ
        reliability_NN derived_VBN in_IN part_NN from_IN the_DT many_JJ repeated_VBN
        measures_NNS ,_, once_RB every_DT five_CD minutes_NNS for_IN 18_CD hours_NNS ,_, that_IN
        measuring_VBG metabolic_JJ rate_NN entails_VBZ )_) ._. Similarly_RB ,_, the_DT very_RB
        small_JJ further_JJ increase_NN in_IN metabolic_JJ rate_NN after_IN
        adrenalectomy_NN was_VBD significant_JJ ._. When_WRB metabolic_JJ rate_NN was_VBD
        normalized_JJ to_TO body_NN weight_NN ,_, expressed_VBD as_IN V_NNP 02_CD (_( Figure_NN 4_CD A_DT )_) ,_,
        the_DT effect_NN of_IN diet_NN was_VBD to_TO reduce_VB this_DT parameter_NN ,_, and_CC
        adrenalectomy_NN increased_VBD very_RB slightly_RB but_CC significantly_RB
        caused_VBD this_DT measure_NN of_IN metabolic_JJ rate_NN ,_, normalized_JJ for_IN body_NN
        mass_NN (_( Figure_NN 4_CD B_NNP )_) ._. The_DT effect_NN of_IN diet_NN on_IN normalized_JJ
        metabolic_JJ rate_NN may_MD be_VB construed_VBN as_IN suggesting_VBG that_IN the_DT
        failure_NN of_IN metabolic_JJ rate_NN to_TO scale_VB proportionally_RB to_TO the_DT
        increase_NN in_IN body_NN weight_NN on_IN the_DT high_JJ fat_JJ diet_NN may_MD have_VB
        contributed_VBN to_TO the_DT maintenance_NN of_IN the_DT obese_NN state_NN ,_,
        especially_RB since_IN the_DT calculated_VBN caloric_JJ intake_NN on_IN the_DT high_JJ
        fat_JJ diet_NN was_VBD less_JJR than_IN on_IN the_DT chow_NN fat_JJ diet_NN ._.
        The_DT key_JJ conclusion_NN to_TO be_VB drawn_VBN from_IN the_DT metabolic_JJ rate_NN
        and_CC food_NN intake_NN data_NNS is_VBZ that_DT effect_NN of_IN adrenalectomy_NN on_IN
        metabolic_JJ rate_NN was_VBD marginal_JJ ,_, and_CC there_EX was_VBD no_DT effect_NN of_IN
        adrenalectomy_NN on_IN food_NN intake_NN ,_, consistent_JJ with_IN the_DT lack_NN of_IN
        effect_NN of_IN adrenalectomy_NN on_IN other_JJ obese_NN phenotypes_NNS ._.
        Nevertheless_RB ,_, with_IN respect_NN to_TO the_DT mechanism_NN of_IN diet-induced_JJ
        obesity_NN ,_, the_DT present_JJ data_NN seem_VBP to_TO indicate_VB that_IN the_DT
        diet-induced_JJ obese_NN mice_NNS maintained_VBD their_PRP$ obesity_NN despite_IN
        apparently_RB decreased_VBD caloric_JJ intake_NN and_CC increased_VBN caloric_JJ
        expenditure_NN ._. Several_JJ explanations_NNS might_MD account_VB for_IN this_DT
        anomalous_JJ result_NN ._. First_LS ,_, caloric_JJ intake_NN is_VBZ calculated_VBN from_IN
        the_DT caloric_JJ density_NN as_RB empirically_RB measured_VBN and_CC reported_VBN by_IN
        the_DT manufacturers_NNS of_IN the_DT diets_NNS ;_: it_PRP remains_VBZ possible_JJ that_IN
        due_JJ to_TO differences_NNS in_IN these_DT measurements_NNS ,_, the_DT true_JJ
        metabolically_RB available_JJ calories_NNS may_MD differ_VB from_IN these_DT
        empirically_RB measured_VBN calories_NNS ._. If_IN so_RB ,_, it_PRP remains_VBZ possible_JJ
        that_IN the_DT high-fat_JJ diet_NN may_MD actually_RB include_VB relatively_RB more_RBR
        metabolically_RB available_JJ calories_NNS than_IN the_DT chow_NN diet_NN ,_, and_CC
        thus_RB that_IN the_DT mice_NNS on_IN the_DT high-fat_JJ diet_NN in_IN reality_NN consumed_VBN
        more_RBR metabolically_RB available_JJ calories_NNS than_IN reflected_VBN by_IN
        simple_JJ calculation_NN of_IN empirically_RB determined_VBN caloric_JJ
        density_NN ._. It_PRP is_VBZ also_RB possible_JJ that_IN calories_NNS were_VBD absorbed_VBN
        more_RBR efficiently_RB on_IN the_DT high-fat_JJ diet_NN ._. In_IN any_DT case_NN ,_, none_NN of_IN
        these_DT considerations_NNS compromise_NN the_DT basic_JJ observation_NN that_DT
        adrenalectomy_NN failed_VBD to_TO reverse_VB diet-induced_JJ obesity_NN ._.
        Since_IN adrenalectomy_NN only_RB reduced_VBD plasma_NN corticosterone_NN
        by_IN about_IN 70_CD %_NN in_IN the_DT obese_NN mice_NNS ,_, rather_RB than_IN completely_RB
        eliminating_VBG the_DT steroid_NN from_IN circulation_NN ,_, it_PRP remains_VBZ
        possible_JJ that_IN even_RB further_JJ reduction_NN of_IN corticosterone_NN
        would_MD produce_VB an_DT effect_NN on_IN diet-induced_JJ obese_NN phenotypes_NNS ._.
        On_IN the_DT other_JJ hand_NN ,_, using_VBG the_DT same_JJ adrenalectomy_NN protocol_NN
        that_WDT produced_VBD a_DT similar_JJ reduction_NN ,_, but_CC not_RB elimination_NN ,_, of_IN
        plasma_NN corticosterone_NN levels_NNS ,_, we_PRP observed_VBD a_DT remarkable_JJ
        reversal_NN of_IN obese_NN phenotypes_NNS in_IN leptin-deficient_JJ 
        ob_NN /_NN ob_NN mice_NNS [_NN 6_CD ]_NN ._. Furthermore_RB ,_, the_DT
        reduction_NN of_IN corticosterone_NN by_IN adrenalectomy_NN in_IN the_DT present_JJ
        study_NN was_VBD sufficient_JJ to_TO produce_VB elevation_NN of_IN pituitary_JJ POMC_NNP
        mRNA_NN (_( as_RB well_RB as_IN hypothalamic_JJ POMC_NNP mRNA_NN )_) ,_, demonstrating_VBG
        that_IN the_DT reduced_VBN levels_NNS were_VBD clearly_RB producing_VBG
        physiological_JJ effects_NNS ._. Consistent_NNP with_IN these_DT results_NNS ,_, high_JJ
        fat_JJ diet_NN attenuates_NNS the_DT effect_NN of_IN adrenalectomy_NN to_TO reverse_VB
        obese_NN phenotypes_NNS in_IN 
        ob_NN /_NN ob_NN mice_NNS [_NN 31_CD ]_NN ._.
      
      
        Conclusions_NNP
        Diet-induced_NNP obesity_NN led_VBN to_TO significant_JJ increases_NNS in_IN
        body_NN weight_NN and_CC adiposity_NN and_CC to_TO the_DT development_NN of_IN glucose_NN
        intolerance_NN ._. Adrenalectomy_NNP reverses_VBZ obese_NN phenotypes_NNS
        including_VBG melanocortin_NN tone_NN in_IN mice_NNS models_NNS of_IN obesity_NN in_IN
        which_WDT plasma_NN glucocorticoid_NN levels_NNS are_VBP elevated_VBD ._. Consistent_NNP
        with_IN results_NNS in_IN ob_NN /_NN ob_NN mice_NNS ,_, adrenalectomy_NN did_VBD stimulate_VB
        hypothalamic_JJ POMC_NNP mRNA_NN associated_VBN with_IN marginal_JJ
        improvements_NNS in_IN glucose_NN tolerance_NN and_CC metabolic_JJ rate_NN in_IN
        mice_NNS made_VBD obese_NN by_IN the_DT high-fat_JJ diet_NN ._. However_RB ,_, these_DT
        responses_NNS to_TO adrenalectomy_NN failed_VBD to_TO reduce_VB food_NN intake_NN ,_,
        body_NN weight_NN ,_, adiposity_NN ,_, or_CC leptin_NN in_IN mice_NNS made_VBD obese_NN by_IN the_DT
        high-fat_JJ diet_NN ,_, in_IN which_WDT the_DT obsese_NN state_NN was_VBD not_RB associated_VBN
        with_IN elevated_JJ glucocorticoid_NN levels_NNS ._. Thus_RB neither_DT
        adrenalectomy_NN nor_CC remarkable_JJ enhancement_NN of_IN hypothalamic_JJ
        POMC_NNP mRNA_NN produced_VBD significant_JJ attenuation_NN of_IN the_DT
        diet-induced_JJ obese_NN phenotype_NN ._. In_IN contrast_NN to_TO other_JJ models_NNS
        of_IN obesity_NN ,_, however_RB ,_, diet-induced_JJ obesity_NN was_VBD not_RB
        associated_VBN with_IN either_DT elevated_VBD glucocorticoid_NN levels_NNS or_CC
        reduced_VBN hypothalamic_JJ POMC_NNP mRNA_NN ._. These_DT data_NNS raise_VBP the_DT
        possibility_NN that_IN potential_JJ anti-obesity_JJ drugs_NNS based_VBN on_IN
        reducing_VBG glucocorticoid_NN tone_NN or_CC elevating_VBG melanocortin_NN tone_NN
        may_MD have_VB limited_JJ efficacy_NN in_IN treating_VBG forms_NNS of_IN obesity_NN in_IN
        which_WDT those_DT systems_NNS are_VBP not_RB perturbed_VBD ._.
      
      
        Methods_NNP
        
          Animals_NNS
          The_DT appropriate_JJ Institutional_NNP Animal_NNP Review_NNP Board_NNP had_VBD
          approved_VBN all_DT studies_NNS ._.
          Male_NNP C_NNP 57_CD Bl_NNP /_NN 6_CD J_NNP mice_NNS were_VBD obtained_VBN at_IN 8_CD months_NNS of_IN age_NN
          from_IN The_DT Jackson_NNP Laboratory_NNP (_( Bar_NNP Harbor_NNP ,_, ME_NNP )_) and_CC were_VBD
          individually_RB housed_VBN with_IN free_JJ access_NN to_TO feed_VB and_CC water_NN
          under_IN 12_CD :_: 12_CD h_NN light-dark_JJ cycle_NN (_( lights_NNS on_IN at_IN 07_CD :_: 00_CD h_NN )_) ._.
          This_DT age_NN was_VBD chosen_VBN because_IN body_NN weight_NN is_VBZ stable_JJ at_IN this_DT
          age_NN ,_, facilitating_VBG interpretation_NN of_IN the_DT expected_VBN opposing_VBG
          effects_NNS of_IN diet_NN and_CC adrenalectomy_NN ._. The_DT C_NNP 57_CD Bl_NNP /_NN 6_CD J_NNP strain_NN
          was_VBD chosen_VBN for_IN susceptibility_NN to_TO obesity_NN on_IN a_DT high_JJ fat_JJ
          diet_NN [_NN 22_CD 32_CD 33_CD 34_CD ]_NN ._. Mice_NNS were_VBD placed_VBN on_IN either_DT a_DT high_JJ
          fat_JJ diet_NN (_( diet_NN #_# D_NNP 12492_CD ;_: Research_NNP Diets_NNP ,_, New_NNP Brunswick_NNP ,_,
          NJ_NNP )_) or_CC regular_JJ rodent_NN chow_NN diet_NN (_( diet_NN #_# 5053_CD ;_: Purina_NNP
          Mills_NNP ,_, Richmond_NNP ,_, IN_IN )_) for_IN a_DT total_NN of_IN five_CD weeks_NNS during_IN
          which_WDT time_NN both_DT body_NN weight_NN and_CC food_NN intake_NN was_VBD monitored_VBN
          daily_RB ._. Cages_NNP were_VBD changed_VBN daily_JJ and_CC a_DT sieve_NN was_VBD used_VBN to_TO
          measure_VB spilt_NN food_NN ._. The_DT high_JJ fat_JJ diet_NN (_( 5_CD ._. 2_LS kcal_NN /_NN g_SYM )_)
          consisted_VBD of_IN 20_CD kcal_NN %_NN protein_NN ,_, 20_CD kcal_NN %_NN carbohydrate_NN and_CC
          60_CD kcal_NN %_NN fat_JJ ,_, while_IN the_DT standard_JJ rodent_NN chow_NN diet_NN (_( 3_CD ._. 08_CD
          kcal_NN /_NN g_SYM )_) consisted_VBD of_IN 23_CD kcal_NN %_NN protein_NN ,_, 64_CD kcal_NN %_NN
          carbohydrate_NN and_CC 11_CD kcal_NN %_NN fat_JJ ._. More_RBR specifically_RB ,_, the_DT
          composition_NN of_IN the_DT high_JJ fat_JJ diet_NN was_VBD (_( per_IN kg_NN )_) :_: casein_NN ,_, 80_CD
          mesh_VB (_( 200_CD g_SYM )_) ,_, L-_NNP cystine_NN (_( 3_CD g_SYM )_) ,_, maltodextrin_NN 10_CD (_( 125_CD g_SYM )_) ,_,
          sucrose_NN (_( 68_CD ._. 8_CD g_SYM )_) ,_, cellulose_NN ,_, BW_NNP 200_CD (_( 50_CD g_SYM )_) ,_, soybean_NN oil_NN
          (_( 25_CD g_SYM )_) ,_, lard_NN (_( 245_CD g_SYM )_) ,_, mineral_NN mix_NN (_( 10_CD g_SYM )_) ,_, dicalcium_NN
          phosphate_NN (_( 13_CD g_SYM )_) ,_, calcium_NN carbonate_NN (_( 5_CD ._. 5_LS g_SYM )_) ,_, potassium_NN
          citrate_NN (_( 16_CD ._. 5_LS g_SYM )_) ,_, vitamin_NN mix_NN (_( 10_CD g_SYM )_) ,_, choline_NN bitartrate_NN
          (_( 2_CD g_SYM )_) and_CC FD_NNP &_CC C_NNP Blue_NNP Dye_NNP #_# 1_CD (_( 0_CD ._. 05_CD g_SYM )_) ._.
          After_IN one_CD week_NN on_IN their_PRP$ respective_JJ diets_NNS ,_, tolerance_NN to_TO
          a_DT glucose_NN load_NN was_VBD tested_VBN by_IN injection_NN of_IN a_DT glucose_NN
          solution_NN (_( 2_CD mg_NN /_NN g_SYM body_NN weight_NN ,_, i_NNP ._. p_NN ._. )_) monitored_VBN for_IN three_CD
          hours_NNS after_IN injection_NN ._. Previous_JJ to_TO the_DT glucose_NN tolerance_NN
          test_NN ,_, food_NN was_VBD removed_VBN from_IN the_DT cages_NNS for_IN five_CD hours_NNS from_IN
          09_CD :_: 00_CD to_TO 14_CD :_: 00_CD hours_NNS ._. After_IN two_CD weeks_NNS on_IN the_DT high-fat_JJ
          diet_NN ,_, mice_NNS from_IN both_DT chow_NN and_CC high-fat_JJ diets_NNS were_VBD either_CC
          bilaterally_RB adrenalectomized_JJ or_CC sham-operated_JJ as_IN
          previously_RB described_VBD [_NN 6_CD ]_NN ._. All_DT mice_NNS were_VBD then_RB given_VBN one_CD
          injection_NN of_IN dexamethasone_NN (_( 45_CD mg_NN /_NN kg_NN body_NN weight_NN i_NNP ._. p_NN ._. )_) to_TO
          facilitate_VB recovery_NN from_IN the_DT surgery_NN ._. The_DT drinking_NN water_NN
          was_VBD replaced_VBN with_IN normal_JJ saline_NN (_( 0_CD ._. 9_CD %_NN NaCl_NNP )_) to_TO compensate_VB
          for_IN the_DT loss_NN of_IN mineralocorticoids_NNS ._. Two_CD weeks_NNS after_IN the_DT
          surgery_NN when_WRB all_DT mice_NNS had_VBD recovered_VBN body_NN weight_NN lost_VBD due_JJ
          to_TO the_DT stress_NN from_IN the_DT surgery_NN ,_, another_DT glucose_NN tolerance_NN
          test_NN was_VBD performed_VBN ,_, and_CC after_IN another_DT week_NN ,_, all_PDT the_DT mice_NNS
          were_VBD placed_VBN into_IN metabolic_JJ cages_NNS in_IN groups_NNS of_IN eight_CD in_IN a_DT
          balanced_JJ design_NN ._. Metabolic_NNP rate_NN was_VBD monitored_VBN
          continuously_RB by_IN indirect_JJ calorimetry_NN for_IN 18_CD hours_NNS as_RB
          previously_RB described_VBD [_NN 35_CD 36_CD ]_NN ._. Food_NNP and_CC water_NN were_VBD
          freely_RB available_JJ in_IN the_DT metabolic_JJ cages_NNS ._. Briefly_NNP ,_, air_NN
          from_IN each_DT cage_NN was_VBD sampled_VBN every_DT five_CD minutes_NNS and_CC oxygen_NN
          and_CC carbon_NN dioxide_NN concentrations_NNS from_IN each_DT sample_NN were_VBD
          measured_VBN independently_RB ._. From_IN the_DT change_NN in_IN oxygen_NN ,_, VO_NNP 
          2_CD was_VBD calculated_VBN as_IN oxygen_NN consumption_NN
          per_IN hour_NN normalized_JJ to_TO body_NN weight_NN (_( ml_NN /_NN kg_NN /_NN hour_NN )_) ._. Heat_NNP
          production_NN was_VBD then_RB calculated_VBN using_VBG the_DT following_JJ
          formula_NN :_: Heat_NNP (_( cal_NN /_NN hour_NN )_) =_SYM (_( (_( 4_CD ._. 33_CD +_NN 0_CD ._. 67_CD ×_NN (_( VCO_NNP 
          2_CD /_NN VO_NNP 
          2_LS )_) )_) ×_NN VO_NNP 
          2_CD ×_NN (_( Body_NNP weight_NN )_) ×_NN 60_CD )_) ._. Therefore_RB ,_,
          the_DT parameter_NN VO_NNP 
          2_CD is_VBZ normalized_JJ to_TO body_NN weight_NN ,_,
          whereas_IN heat_NN production_NN is_VBZ not_RB normalized_JJ to_TO body_NN weight_NN
          and_CC so_RB reflects_VBZ total_JJ energy_NN expenditure_NN ._.
          The_DT mice_NNS were_VBD sacrificed_JJ toward_IN the_DT end_NN of_IN the_DT light_JJ
          period_NN at_IN the_DT end_NN of_IN the_DT day_NN in_IN the_DT metabolic_JJ cages_NNS
          (_( between_IN 17_CD :_: 00_CD and_CC 19_CD :_: 00_CD h_NN )_) by_IN decapitation_NN after_IN a_DT brief_JJ
          exposure_NN to_TO carbon_NN dioxide_NN and_CC trunk_NN blood_NN was_VBD collected_VBN ;_:
          we_PRP have_VBP verified_VBN in_IN pilot_NN studies_NNS that_IN this_DT method_NN of_IN
          sacrifice_NN does_VBZ not_RB increase_VB plasma_NN corticosterone_NN above_IN
          levels_NNS observed_VBD without_IN carbon_NN dioxide_NN exposure_NN ._. Brains_NNP
          for_IN Northern_NNP blot_NN analysis_NN were_VBD quickly_RB removed_VBN and_CC the_DT
          hypothalamus_JJ was_VBD dissected_VBN out_IN ,_, frozen_VBN on_IN dry_JJ ice_NN and_CC
          stored_VBD at_IN -_: 70_CD °_NN C_NNP until_IN use_NN as_IN described_VBN previously_RB
          [_NN Makimura_NNP ,_, 2000_CD #_# 5346_CD ;_: [_NN Mizuno_NNP ,_, 1999_CD #_# 5302_CD ]_NN ._. In_IN addition_NN ,_,
          the_DT anterior_NN lobe_NN of_IN the_DT pituitary_JJ was_VBD also_RB removed_VBN and_CC
          frozen_VBN on_IN dry_JJ ice_NN and_CC stored_VBD at_IN -_: 70_CD °_NN C_NNP until_IN use_NN ._.
          Epididymal_NNP white_JJ adipose_NN tissue_NN was_VBD also_RB removed_VBN ,_, weighed_VBD
          and_CC frozen_VBN on_IN dry_JJ ice_NN and_CC stored_VBD at_IN -_: 70_CD °_NN C_NNP until_IN use_NN ._. The_DT
          four_CD groups_NNS that_WDT resulted_VBD from_IN this_DT experimental_JJ design_NN
          was_VBD as_IN follows_VBZ :_: chow_NN sham-operated_JJ (_( n_NN =_SYM 8_CD )_) ,_, chow_NN
          adrenalectomized_JJ (_( n_NN =_SYM 10_CD )_) ,_, diet_NN sham-operated_JJ (_( n_NN =_SYM 8_CD )_) ,_, and_CC
          diet_NN adrenalectomized_JJ (_( n_NN =_SYM 11_CD )_) ._. Successful_JJ adrenalectomy_NN
          was_VBD verified_VBN by_IN visual_JJ inspection_NN at_IN the_DT time_NN of_IN
          sacrifice_NN ,_, as_RB well_RB as_IN by_IN the_DT induction_NN of_IN pituitary_JJ
          proopiomelanocortin_NN (_( POMC_NNP )_) mRNA_NN levels_NNS and_CC the_DT reduction_NN
          in_IN serum_NN corticosterone_NN levels_NNS ._.
        
        
          Blood_NNP chemistry_NN
          Blood_NNP glucose_NN levels_NNS were_VBD measured_VBN by_IN a_DT Lifescan_NNP
          One-_NNP Touch_NNP II_NNP glucose_NN meter_NN (_( Johnson_NNP &_CC Johnson_NNP ,_,
          Mountain_NNP View_NNP ,_, CA_NNP )_) ._. Serum_NNP insulin_NN and_CC leptin_NN peptide_NN
          levels_NNS were_VBD assayed_JJ by_IN ELISA_NNP with_IN commercial_JJ kits_NNS
          (_( CRYSTAL_NNP CHEM_NNP INC_NNP ._. ,_, Chicago_NNP ,_, IL_NNP )_) and_CC serum_NN corticosterone_NN
          was_VBD assayed_JJ by_IN RIA_NNP with_IN a_DT commercial_JJ kit_NN (_( ICN_NNP
          Pharmaceuticals_NNP Inc_NNP ._. ,_, Costa_NNP Mesa_NNP Ca_NNP )_) ._.
        
        
          Northern_JJ blot_NN analysis_NN
          Hypothalamic_NNP proopiomelanocortin_NN (_( POMC_NNP )_) and_CC
          agouti-related_JJ peptide_NN (_( AGRP_NNP )_) mRNA_NN and_CC pituitary_JJ POMC_NNP
          mRNA_NN were_VBD measured_VBN by_IN Northern_NNP blot_NN analysis_NN as_RB
          previously_RB described_VBD [_NN 6_CD ]_NN ._. Briefly_NNP ,_, total_JJ RNA_NNP was_VBD
          extracted_VBN in_IN TRIzol_NNP (_( GIBCO_NNP BRL_NNP ,_, Gaithersburg_NNP ,_, MD_NNP )_) and_CC
          three_CD micrograms_NNS of_IN total_JJ RNA_NNP from_IN hypothalamus_JJ ,_,
          estimated_VBN by_IN spectrophotometer_NN and_CC verified_VBN by_IN gel_NN
          electrophoresis_NNS ,_, was_VBD subjected_VBN to_TO Northern_NNP blot_NN analysis_NN
          to_TO measure_VB POMC_NNP and_CC AGRP_NNP mRNA_NN ._. Three_CD micrograms_NNS of_IN total_JJ
          RNA_NNP from_IN anterior_NN pituitary_JJ was_VBD used_VBN to_TO measure_VB pituitary_JJ
          POMC_NNP mRNA_NN ._. Total_NNP RNA_NNP was_VBD denatured_JJ in_IN a_DT mixture_NN of_IN
          glyoxal_NN and_CC dimethyl_NN sulfoxide_NN for_IN 1_CD hr_NN at_IN 50_CD °_NN C_NNP and_CC
          electrophoresed_JJ for_IN 60_CD minutes_NNS on_IN a_DT 10_CD mM_NN sodium_NN
          phosphate_NN agarose_NN gel_NN ._. The_DT RNA_NNP was_VBD transferred_VBN to_TO an_DT
          Immobilon_NNP membrane_NN over_IN night_NN in_IN 20_CD ×_NN standard_JJ saline_NN
          citrate_NN (_( SSC_NNP )_) by_IN capillary_JJ action_NN ._. The_DT membrane_NN was_VBD
          subsequently_RB baked_JJ for_IN several_JJ hours_NNS at_IN 80_CD °_NN C_NNP and_CC
          cross-linked_JJ with_IN UV_NNP light_JJ at_IN 33000_CD uJ_NN /_NN cm_NN 2_CD energy_NN ._. The_DT
          membranes_NNS were_VBD prehybridized_JJ in_IN a_DT commercial_JJ Ultrahyb_NNP
          buffer_NN (_( Ambion_NNP ,_, Inc_NNP ._. ,_, Austin_NNP ,_, TX_NNP )_) for_IN 1_CD to_TO 2_CD hours_NNS at_IN
          65_CD °_NN C_NNP ._. Hybridization_NNP was_VBD carried_VBN out_IN in_IN the_DT same_JJ buffer_NN
          with_IN a_DT single_JJ stranded_VBN internally_RB labeled_VBN 32_CD P_NN probe_NN over_IN
          night_NN at_IN 42_CD °_NN C_NNP ._. The_DT membranes_NNS were_VBD washed_VBN in_IN 1_CD ×_NN SSC_NNP /_NN 0_CD ._. 1_LS %_NN
          SDS_NNP for_IN 15_CD minutes_NNS at_IN room_NN temperature_NN twice_RB followed_VBN by_IN
          two_CD more_JJR washes_NNS with_IN 0_CD ._. 1_CD ×_NN SSC_NNP /_NN 0_CD ._. 1_LS %_NN SDS_NNP for_IN 15_CD minutes_NNS at_IN
          room_NN temperature_NN ._. Finally_RB ,_, the_DT membrane_NN was_VBD washed_VBN in_IN 0_CD ._. 1_CD
          ×_NN SSC_NNP /_NN 0_CD ._. 1_LS %_NN SDS_NNP for_IN 3_CD hours_NNS at_IN 42_CD °_NN C_NNP ,_, and_CC exposed_VBD to_TO a_DT
          phosphoimager_NN screen_NN over_IN night_NN ._. The_DT Northern_NNP blots_NNS were_VBD
          probed_JJ using_VBG single-stranded_JJ internally_RB labeled_VBN DNA_NNP
          probes_NNS as_IN described_VBN previously_RB [_NN 6_CD ]_NN ._. Membranes_NNP were_VBD
          re-probed_JJ and_CC hybridized_JJ with_IN 32_CD P-_NNP labeled_VBD probe_NN encoding_VBG
          18_CD S_NNP ribosomal_JJ RNA_NNP and_CC all_DT signals_NNS were_VBD normalized_JJ to_TO this_DT
          18_CD S_NNP signal_NN upon_IN quantification_NN ._. The_DT total_JJ integrated_VBN
          densities_NNS of_IN hybridization_NN signals_NNS were_VBD determined_VBN by_IN
          phosphoimager_NN (_( STORM_NNP 860_CD ,_, Molecular_NNP Dynamics_NNP ,_, Sunnyvale_NNP ,_,
          CA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP analysis_NN was_VBD performed_VBN by_IN a_DT two-way_JJ
          analysis_NN of_IN variance_NN (_( ANOVA_NNP )_) followed_VBN ,_, when_WRB indicated_VBN by_IN
          appropriate_JJ p-values_JJ (_( p_NN <_NN 0_CD ._. 05_CD )_) ,_, by_IN Tukey-_NNP Kramer_NNP
          post-hoc_JJ test_NN ,_, using_VBG the_DT JMP_NNP statistical_JJ package_NN
          implemented_VBN on_IN the_DT Macintosh_NNP operating_VBG system_NN ._. For_IN the_DT
          glucose_NN tolerance_NN tests_NNS and_CC metabolic_JJ rate_NN measurements_NNS ,_,
          a_DT two-way_JJ ANOVA_NNP (_( treatment_NN ×_NN time_NN )_) was_VBD performed_VBN using_VBG
          the_DT JMP_NNP statistical_JJ package_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD (_( HM_NNP )_) carried_VBD out_RP the_DT animal_NN experiments_NNS ,_,
        molecular_JJ assays_NNS ,_, and_CC statistical_JJ analysis_NN and_CC drafted_VBD the_DT
        manuscript_NN ._. Author_NN 2_CD (_( TMM_NNP )_) participated_VBD in_IN the_DT animal_NN
        surgeries_NNS ._. Author_NN 3_CD (_( JB_NNP )_) carried_VBD out_RP all_PDT the_DT hormone_NN
        assays_NNS ._. Author_NN 4_CD (_( JHS_NNP )_) contributed_VBD to_TO the_DT hormone_NN assays_NNS ._.
        Author_NN 5_CD (_( CVM_NNP )_) conceived_VBD of_IN the_DT study_NN ,_, participated_VBD in_IN the_DT
        design_NN and_CC coordination_NN of_IN the_DT studies_NNS ,_, and_CC helped_VBD draft_NN
        the_DT manuscript_NN ._.
      
      
        Acknowledgments_NNP
        These_DT studies_NNS were_VBD supported_VBN by_IN the_DT National_NNP Institute_NNP
        on_IN Aging_NNP (_( AG_NNP 19934_CD -_: 01_CD )_) ._.
      
    
  
